Royalty Pharma (RPRX) PT Raised to $51 at Morgan Stanley
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Price: $59.13 +0.90%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn raised the price target on Royalty Pharma (NASDAQ: RPRX) to $51.00 (from $50.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
- Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker
- SM Prime Holdings, Inc (SMPH:PM) (SPHXF) PT Lowered to PHP21 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
